THE FACTORS RELATED TO H. PYLORI INFECTION RESISTANCE AFTER ERADICATION OR ITS RECURRENCE IN SULAIMANI CITY
Main Article Content
Hazhan Nawzad Ahmad
Makwan Mohammed Abdulkareem*
Muhamad Abdularahman Muhamad Alshekhani
Helicobacter pylori (H. pylori) infection can lead to peptic ulcers, chronic gastritis, lymphoma and gastric cancer. This study aimed to assess the factors related to H. pylori resistance after eradication and its recurrence after 6 months. 574 patients tested for H. pylori and those who positive has been assessed for recurrence after 6 months or resistance to treatment and factors related to recurrence in correlation with demographic data. 51% of men and 49% of women were still testing positive for H. pylori after receiving treatment. The majority of patients who tested positive again for H. pylori were taking clarithromycin-based triple therapy, with only a small percentage being treated with levofloxacin, rate of resistance and recurrence were 23.54% and 8.7%, respectively. Most common symptoms after recurrence were epigastric pain and nausea (62.96%) and dyspepsia (55.55%). The highest rate of recurrence is related to O+ blood group, which is 47.82%. Recurrence rate after H. pylori eradication by standard therapy (clarithromycin triple treatment) or levofloxacin-based therapy is 8.7%. Poor sanitation, low income, and treatments regimens are independent risk factors for recurrence of H. pylori. Reducing the frequency of eating outdoors and treating family members may reduce H. pylori infection recurrence.
Abasiyanik, M. F., Tunc, M., & Salih, B. A. (2004). Enzyme immunoassay and immunoblotting analysis of Helicobacter pylori infection in Turkish asymptomatic subjects. Diagnostic Microbiology and Infectious Disease, 50(3), 173–177.
Ahmad, H. N., & Abdulkareem, M. M. (2024). Diagnostic and therapeutic challenges of Helicobacter pylori Infection: A narrative review. JCMCRI.
Al-Moslih, M. (2012). Serological Diagnosis of Certain Human, Animal and Plant Diseases. BoD–Books on Demand.
Alazmi, W. M., Siddique, I., Alateeqi, N., & Al-Nakib, B. (2010). Prevalence of Helicobacter pylori infection among new outpatients with dyspepsia in Kuwait. BMC Gastroenterology, 10, 1–4.
Alkout, A. M., Blackwell, C. C., & Weir, D. M. (2000). Increased inflammatory responses of persons of blood group O to Helicobacter pylori. The Journal of Infectious Diseases, 181(4), 1364–1369.
Asrat, D., Nilsson, I., Mengistu, Y., Ashenafi, S., Ayenew, K., Al-Soud, W. A., Wadström, T., & Kassa, E. (2004). Prevalence of Helicobacter pylori infection among adult dyspeptic patients in Ethiopia. Annals of Tropical Medicine & Parasitology, 98(2), 181–189.
Bauer, B., & Meyer, T. F. (2011). The human gastric pathogen Helicobacter pylori and its association with gastric cancer and ulcer disease. Ulcers, 2011(1), 340157.
Franchini, M., Capra, F., Targher, G., Montagnana, M., & Lippi, G. (2007). Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thrombosis Journal, 5, 1–5.
Guevara, B., & Cogdill, A. G. (2020). Helicobacter pylori: a review of current diagnostic and management strategies. Digestive Diseases and Sciences, 65(7), 1917–1931.
Heneghan, M. A., Moran, A. P., Feeley, K. M., Egan, E. L., Goulding, J., Connolly, C. E., & McCarthy, C. F. (1998). Effect of host Lewis and ABO blood group antigen expression on Helicobacter pylori colonisation density and the consequent inflammatory response. FEMS Immunology & Medical Microbiology, 20(4), 257–266.
Hooi, J. K. Y., Lai, W. Y., Ng, W. K., Suen, M. M. Y., Underwood, F. E., Tanyingoh, D., Malfertheiner, P., Graham, D. Y., Wong, V. W. S., & Wu, J. C. Y. (2017). Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology, 153(2), 420–429.
Jafar, S. K., Abdulkareem, M., & Mohammed, M. O. (2023). The Relation between Chronic Viral Hepatitis B Infection and Helicobacter Pylori Infection. Kirkuk Journal of Medical Sciences, 11(1), 75–100.
Jaff, M. S. (2010). Higher frequency of secretor phenotype in O blood group–its benefits in prevention and/or treatment of some diseases. International Journal of Nanomedicine, 901–905.
Jaff, M. S. (2011). Relation between ABO blood groups and Helicobacter pylori infection in symptomatic patients. Clinical and Experimental Gastroenterology, 221–226.
Kanbay, M., Gür, G., Arslan, H., Yilmaz, U., & Boyacioĝlu, S. (2005). The relationship of ABO blood group, age, gender, smoking, and Helicobacter pylori infection. Digestive Diseases and Sciences, 50, 1214–1217.
Kotilea, K., Bontems, P., & Touati, E. (2019). Epidemiology, diagnosis and risk factors of Helicobacter pylori infection. Helicobacter Pylori in Human Diseases: Advances in Microbiology, Infectious Diseases and Public Health Volume 11, 17–33.
Malaty, H. M., El-Kasabany, A., Graham, D. Y., Miller, C. C., Reddy, S. G., Srinivasan, S. R., Yamaoka, Y., & Berenson, G. S. (2002). Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. The Lancet, 359(9310), 931–935.
Mégraud, F. (2004). Basis for the management of drug-resistant Helicobacter pylori infection. Drugs, 64, 1893–1904.
Mohammed, M. O., Bayz, H. H., & Maarouf, F. B. (2017). Clinical, endoscopic and urea breath test among dyspeptic patients referred to Kurdistan center for gastroenterology and hepatology in sulaimani. Kurdistan Journal of Applied Research, 2(2), 89–95.
Mohammed, O. M., Arif, D. M., & Mohammed, M. A. (2020). The Evaluation Of Triple, Quadruple, And Levofloxacin-Based Therapy In The Management Of Helicobacter Pylori Infection Among Dyspeptic Patients. J Sulaimani College of Medicine, 9, 45–51.
Morgan, D. R., Torres, J., Sexton, R., Herrero, R., Salazar-Martínez, E., Greenberg, E. R., Bravo, L. E., Dominguez, R. L., Ferreccio, C., & Lazcano-Ponce, E. C. (2013). Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. Jama, 309(6), 578–586.
Murray, L. J., McCRUM, E. E., Evans, A. E., & Bamford, K. B. (1997). Epidemiology of Helicobacter pylori infection among 4742 randomly selected subjects from Northern Ireland. International Journal of Epidemiology, 26(4), 880–887.
Ndip, R. N., Malange, A. E., Akoachere, J. F. T., MacKay, W. G., Titanji, V. P. K., & Weaver, L. T. (2004). Helicobacter pylori antigens in the faeces of asymptomatic children in the Buea and Limbe health districts of Cameroon: a pilot study. Tropical Medicine & International Health, 9(9), 1036–1040.
O’Connor, A., Furuta, T., Gisbert, J. P., & O’Morain, C. (2020). Review–treatment of Helicobacter pylori infection 2020. Helicobacter, 25, e12743.
Petrović, M., Artiko, V., Novosel, S., Ille, T., Šobić-Šaranović, D., Pavlović, S., Jakšić, E., Stojković, M., Antić, A., & Obradović, V. (2011). Relationship between Helicobacter pylori infection estimated by 14C-urea breath test and gender, blood groups and Rhesus factor. Hellenic Journal of Nuclear Medicine, 14(1), 21–24.
Salih, B. A. (2009). Helicobacter pylori infection in developing countries: the burden for how long? Saudi Journal of Gastroenterology, 15(3), 201–207.
Stefano, K., Marco, M., Federica, G., Laura, B., Barbara, B., Gioacchino, L., & Gian, L. de’Angelis. (2018). Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Bio Medica: Atenei Parmensis, 89(Suppl 8), 72.
Torres, J., Lopez, L., Lazcano, E., Camorlinga, M., Flores, L., & Munoz, O. (2005). Trends in Helicobacter pylori infection and gastric cancer in Mexico. Cancer Epidemiology Biomarkers & Prevention, 14(8), 1874–1877.
Wei, S., Li, X., Wang, J., Wang, Y., Zhang, C., Dai, S., Wang, X., Deng, X., Zhao, L., & Shan, B. (2021). Outer membrane vesicles secreted by Helicobacter pylori transmitting gastric pathogenic virulence factors. ACS Omega, 7(1), 240–258.
Zou, Y., Qian, X., Liu, X., Song, Y., Song, C., Wu, S., An, Y., Yuan, R., Wang, Y., & Xie, Y. (2020). The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis. Helicobacter, 25(4), e12714.
